Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis

Table 4 Associations of confirmed SARS-CoV-2 infection. Bivariable analysis

	OR	95% CI	p	AUC
Hypertension
Hypertension	1.73	1.14 to 2.64	0.01	0.66
PDN	3.04	2.09 to 4.43	< 0.001
Hypertension	2.04	1.18 to 3.53	0.01	0.61
csDMARDs	1.74	0.53 to 5.72	0.37
Hypertension	1.81	1.47 to 2.24	< 0.001	0.64
b/tsDMARDs	0.46	0.18 to 1.21	0.12
Home lockdown
Home lockdown	0.55	0.35 to 0.85	0.008	0.67
PDN	3.20	1.97 to 5.18	< 0.001
Home lockdown	0.62	0.40 to 0.95	0.03	0.59
csDMARDs	1.58	0.66 to 3.77	0.31
Home lockdown	0.63	0.46 to 0.85	0.002	0.63
b/tsDMARDs	0.51	0.11 to 2.29	0.38
Contacts with COVID-19
Contacts with COVID-19	12.74	2.38 to 68.30	0.003	0.74
PDN	3.14	1.72 to 5.73	< 0.001
Contacts with COVID-19	13.33	2.08 to 85.40	0.006	0.68
csDMARDs	1.77	0.60 to 5.21	0.30
Contacts with COVID-19	11.76	1.74 to 79.51	0.01	0.68
b/tsDMARDs	0.48	0.12 to 1.92	0.30
Treatment
PDN	2.70	1.34 to 5.46	0.006	0.65
csDMARDs	1.56	0.45 to 5.35	0.48
PDN	2.67	1.84 to 3.86	< 0.001	0.67
b/tsDMARDs	0.51	0.18 to 1.44	0.21
csDMARDs	1.72	0.51 to 5.84	0.38	0.62
b/tsDMARDs	0.47	0.15 to 1.53	0.21

PDN prednisone, csDMARDs conventional synthetic disease-modifying anti-rheumatic drugs, b/ts DMARDs biological/targeted synthetic disease-modifying anti-rheumatic drugs

ISSN: 1478-6362